ÑÎÂÐÅÌÅÍÍÎÅ ÑÎÑÒÎßÍÈÅ ËÅ×ÅÍÈß ÄÎÐÑÀËÃÈÉ Резюме. Вопросы лечения дорсалгий, а именно неврологических проявлений при этой нозологии, остаются достаточно актуальной проблемой современной практической медицины. По мнению авторов, наиболее эффективным является использование кинезиотерапевтических методов преимущественно в комплексе с другими видами патогенетического лечения.

Parkinson's disease (PD) is a progressive disease and the incidence increases markedly with age, treatment has significantly improved the quality of life of patients with PD, but statistics show that these patients continue to show shorter life expectancies compared to the general population. Aim of the study. To investigate the features of changes in energy balance and mitochondrial dysfunction on the basis of experimental studies in rats in the modeling of PD and justify the development of possible treatment regimens with specific neuroprotective effects on the dopaminergic system. Materials and methods. The study was carried out on 90 Wistar rats at the age of 6 months weighing 220-290 grams. Parkinsonism was induced by the administration of the

The pathogenetic aspects of Parkinson's disease and possible ways of their correction. Buchakchyiska N. M., Maramukha V. I., Maramukha I. V. Purpose of the study. The purpose of the work is to summarize the data available in the literature regarding the role of shock proteins, in particular the HSP 70 protein, in the mechanisms of endogenous neuroprotection and neurodegradation in Parkinson's disease (PD). The article also aims at determining the possible pathogenetic stages of the disease development and the place of mitochondrial dysfunction, apoptotic and antiapoptotic systems in these processes. The modulation of PD MPTP model can help to identify possible ways of influencing the pathogenetic mechanisms of neurodegenerative changes in structures of the extrapyramidal system by stimulating the processes of neuroprotection and slowing of neurodegradation owing to inducing protein level synthesis. After statistical processing of the obtained results, one can interpolate the obtained data on idiopathic PD in the population by matching the relevant neurodegenerative process markers found in the experiment with indicators in PD patients. As a result, it may hypothetically be possible to develop the use of personalized pathogenetic therapy for PD. Keywords: Parkinson’s disease, neuroprotection, heat shock

Parkinson's disease (PD) is one of the most common neurodegenerative diseases in the elderly. The aim of the study. To study apoptotic processes and their role in the formation of dopaminergic neurodegeneration and to develop new treatment regimens with a specific neuroprotective effect on the dopaminergic system. Materials and methods. The study was carried out on 90 Wistar rats at the age of 6 months weighing 220–290 grams. Parkinsonism was induced by the administration of the neurotoxin MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) to experimental rats with neuroprotective treatment: I – Intact (passive control); II – animals with experimental Parkinson's disease (PD, active control); III – PD + Amantadine (AM) IV – PD + AM + Cerebrocurin; V – PD + AM + Pramistar; VI – PD + AM + Gliatilin; VII – PD + AM + Noofen; VIII – PD + AM + Pronoran; IX – PD + AM + Melatonin. Results. The obtained data indicate that neuroprotective therapy of PD with drugs such as melatonin, cerebrocurin, pronoran and gliatilin in combination with amantadine leads to an increase in the expression of the HIF-1α, HIF-3α, HSP70 genes, bcl-2 proteins and decrease c-fos proteins with caspase-3 as markers of apoptosis and can also serve as a molecular marker for the activation of endogenous neuroprotection mechanisms under the conditions of an experimental PD. Conclusions. The study experimentally demonstrated a new target of neuroprotection in PD conditions – apoptosis of dopamine-producing neurons and substantiated modulators of this process – drugs for combined therapy with amantadine (melatonin, cerebrocurin, pronoran and gliatilin) ​​as promising drugs for the treatment of PD.

Parkinson's disease is a progressive disease with moderate age of the beginning of 55 years. Over time, symptoms worsen, and although levodopa has significantly improved the quality of life of patients with PD, statistics show that these patients continue to show shorter life expectancies compared to the general population. In addition, most patients with PD suffer from significant movement disorders after 5–10 years of illness, even with qualified treatment with available symptomatic drugs.